Compare Sunrun Inc (RUN) vs Sanofi SA (SNY) Price & Performance

Sunrun (RUN) trades at $7.59, down 0.26% on the day, with a bearish technical outlook despite strong analyst support. The company shows mixed fundamentals with impressive earnings beats but negative operating cash flow and high debt levels. Recent developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions, providing potential growth catalysts amid solar sector volatility.

The stock presents a value opportunity with low P/E (5.16) and P/B (0.52) ratios, but faces significant headwinds from high borrowing costs and negative cash flows. Analyst consensus remains strongly bullish with a $15.40 price target, though technical indicators suggest near-term pressure. Investors must weigh the attractive valuation against execution risks in a challenging financing environment.

Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.

SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.